PARIS — L’Oréal has taken a minority stake in Swiss longevity biotech company Timeline.

Terms of the deal, which was made through the wonder giant’s strategic enterprise capital fund Business Opportunities for L’Oréal Development, weren’t disclosed.

Timeline was founded in 2007 by Chris Rinsch and Patrick Aebischer as a by-product of the Swiss Federal Institute of Technology. It develops solutions for longevity within the food, business and health categories.

Rinsch serves as Timeline president, and Aebischer is its chairman.

“Timeline has developed a proprietary molecule, Mitopure, that recycles and rejuvenates aging mitochondria, the powerhouses of cells,” L’Oréal said in a press release Tuesday. “This breakthrough technology is backed by greater than a decade of research by distinguished scientists, multiple gold standard clinical studies and an unparalleled mental property portfolio. The investment will enable Timeline to further develop its unique technology and expand operations, while enabling future collaboration with L’Oréal.”

The sweetness industry’s lexicon — and focus — keep expanding. Health, then well-being, were buzzwords within the recent past. Now, with the convergence of those two and scientific advances, longevity is becoming a key talking point and market shapeshifter.

“Longevity is about living healthier for longer, and L’Oréal has been working for greater than a decade to grasp and anticipate what this might mean for beauty,” said Barbara Lavernos, deputy chief executive officer and in control of research, innovation and technology at L’Oréal. “Longevity adds a latest dimension to beauty, focused on predicting, correcting and even reversing the aging of our skin, scalp and hair. Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and wonder.”

“This strategic collaboration reflects the breakthrough multidimensional approach that we’ve at all times believed is mandatory to make meaningful advancements for longevity and health span,” Aebischer said. 

BOLD has been ramping up its acquisition pace. On Jan. 9 it revealed it had acquired environmental water-tech start-up Gjosa. Investments for the enterprise capital fund last 12 months included in Shinehigh Innovation and in Genomatica Inc., an initiative centered on developing, producing and commercializing biotechnology-based alternatives to key beauty product ingredients.